Despite the success of antiretroviral therapy (ART) for people living with HIV, lifelong
treatment is required and there is no cure. HIV can integrate in the host genome and persist …

Antiretroviral therapy (ART) inhibits HIV replication but is not curative. During ART, the
integrated HIV genome persists indefinitely within CD4+ T cells and perhaps other cells …

HIV-1 persists in a latent reservoir in resting CD4+ T cells despite antiretroviral therapy
(ART). The reservoir decays slowly over the first 7 years of ART (t 1/2= 44 months). However …

HIV-1-infected cells that persist despite antiretroviral therapy (ART) are frequently
considered" transcriptionally silent," but active viral gene expression may occur in some …

Sustained, drug-free control of HIV-1 replication is naturally achieved in less than 0.5% of
infected individuals (here termed 'elite controllers'), despite the presence of a replication …

HIV-1 infection remains a public health problem with no cure. Anti-retroviral therapy (ART) is
effective but requires lifelong drug administration owing to a stable reservoir of latent …

A stable latent reservoir for HIV-1 in resting CD4+ T cells is the principal barrier to a cure,–.
Curative strategies that target the reservoir are being tested, and require accurate, scalable …

Individuals infected with HIV-1 require lifelong antiretroviral therapy, because interruption of
treatment leads to rapid rebound viraemia. Here we report on a phase 1b clinical trial in …

Antiretroviral therapy can effectively block HIV-1 replication and prevent or reverse
immunodeficiency in HIV-1-infected individuals. However, viral replication resumes within …

The development of antiretroviral therapy for the prevention and treatment of HIV infection
has been marked by a series of remarkable successes. However, the efforts to develop a …